Soleno Therapeutics, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno Therapeutics" or the "Company") (SLNO). Impacted investors are advised to contact the firm now.

The investigation concerns whether Soleno Therapeutics and certain of its officers and/or directors have allegedly engaged in securities fraud or other unlawful business practices.

The investigation focuses on allegations that Soleno Therapeutics and its executives may have made misleading statements and omissions regarding the safety and commercial prospects of VYKAT XR, the Company’s sole FDA-approved product. Between February 27, 2025 and August 15, 2025, Soleno Therapeutics reported strong momentum, market readiness, and safety profile of VYKAT XR.

However, on August 15, 2025, an investor report by Scorpion Capital alleged that multiple children had been hospitalized for heart failure following VYKAT XR treatment. The report further called into question the integrity of the Company’s launch data and suggested that previously reported positive metrics were potentially misleading.

According to the allegations, Soleno Therapeutics’s disclosures failed to mention adverse events and potential risks associated with VYKAT XR, despite FDA warnings regarding fluid overload and heart risks. The report also raised concerns about data integrity in clinical trials and suggested that Company insiders may have known or recklessly disregarded these issues.

On this news, Soleno Therapeutics’s stock price fell $5.72 per share, or 7.4%, to close at $71.63 on Aug. 15, 2025, erasing hundreds of millions of dollars in market capitalization.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.